Exagen Launch of Novel Biomarker PC4d Associated with Thrombosis in Lupus

Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests. ALBUQUERQUE, NM and SAN DIEGO, CA, Oct 12, 2018 (GLOBE NEWSWIRE) – Exagen Diagnostics, a leader in autoimmune life sciences, announced today that it will be updating the popular AVISE® SLE Monitor test to include levels of platelet-bound C4d (PC4d). Exagen will be the only …

Exagen Featured in Eight Scientific Presentations at The 2018 ACR/ARHP Annual Meeting in Chicago, IL

Leading immunology laboratory continues strides with first ever economic impact data for AVISE Lupus.   ALBUQUERQUE, NM and SAN DIEGO, CA, Oct 02, 2018 (GLOBE NEWSWIRE)– Exagen Diagostics, the exclusive providers of AVISE® testing, announced today that a total of eight scientific presentations have been accepted at this year’s 2018 ACR/ARHP Annual Meeting being held in Chicago, IL, October 19-24. …

Exagen, Maker of AVISE Testing, Announces First Blood Test for Anti-CarP, a Breakthrough Bio-marker for Rheumatoid Arthritis

Novel Test Now Available to Aid in Detection and Management of Widespread Debilitating Condition San Diego, CA and Albuquerque, NM, Sep 11, 2018 (GLOBE NEWSWIRE) – Exagen Diagnostics, the leader in specialty rheumatology testing, announced today availability of the first validated blood test to detect autoantibodies against carbamylated proteins (anti-CarP). Studies show that this novel test can add valuable information …